Journal
DIABETES OBESITY & METABOLISM
Volume 25, Issue 9, Pages 2634-2641Publisher
WILEY
DOI: 10.1111/dom.15184
Keywords
antidiabetic drug; GLP-1; pharmacodynamics; pharmacokinetics; phase I-II study; weight control
Categories
Ask authors/readers for more resources
This study evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of orforglipron, an oral GLP-1RA. The drug had a long half-life and showed similar efficacy and safety as injectable GLP-1RAs, suggesting potential for further clinical development.
Aim: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of orforglipron (LY3502970), an oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1RA) in healthy participants. Materials and Methods: This was a double-blind, placebo-controlled, Phase 1 study. Overtly healthy adults aged 18 to 65 years with body mass index of 20 to 40 kg/m(2) and glycated haemoglobin concentration of 47.5 mmol/mol (< 6.5%) were eligible. In Part A, participants received single-dose orforglipron, with four cohorts receiving escalating doses (0.3-6 mg). In Part B, participants received 4 weeks of daily repeated oral orforglipron with doses escalating weekly to four different final target doses (2-24 mg). Results: Ninety-two participants enrolled and received at least one study drug dose (32 in Part A [mean age 43.4 years] and 60 in Part B [mean age 42.5 years]). The most common adverse events were gastrointestinal tract-related. Pharmacokinetics were approximately dose proportional, and the mean t(1/2) was 24.6 to 35.3 hours after a single dose (0.3-6 mg). On Day 28, the mean t(1/2) was 48.1 to 67.5 hours across the dose range (2-24 mg). Substantial reductions in body weight of up to 5.4 kg were observed after 4 weeks in orforglipron-treated participants, compared to a reduction of 2.4 kg with placebo (P < 0.05). Orforglipron decreased fasting glucose levels across Days 1 to 28, and gastric emptying was delayed on Day 28. Conclusions: Orforglipron's long half-life (25-68 hours) allows once-daily oral dosing, without water and food restrictions. Orforglipron had a pharmacodynamic and safety profile similar to that of injectable GLP-1RAs, which supports continued clinical development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available